Dynamic Plasticity of Prostate Cancer Intermediate Cells During Androgen Receptor Targeted Therapy

2021 ◽  
Author(s):  
Harkirat Sandhu ◽  
Xianxiao Zhou ◽  
Julia Zhao ◽  
Alexander Rialdi ◽  
John Sfakianos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Intermediate Cells ◽  
Dynamic Plasticity

Abstract 16180: Cardiovascular Adverse Events Associated With Androgen Receptor-targeted Therapy Used in the Treatment of Prostate Cancer

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Bishesh Shrestha ◽  
Sugam Gouli ◽  
Asis Shrestha
Keyword(s):  
Prostate Cancer ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Adverse Event ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Coronary Artery ◽  
Adverse Events ◽  
Cardiogenic Shock ◽  
Cardiovascular Adverse Event

Introduction: Prostate cancer is the second most common cancer in males. Its risk increases with age. So does the risk for cardiovascular disease. Androgen receptor-targeted therapy is now recommended to be added to androgen-deprivation therapy in the treatment of prostate cancer. We present common cardiovascular adverse events seen with the use of anti-androgens medication: abiraterone, enzalutamide, apalutamide, and darolutamide. Methods: We conducted a meta-analysis of 13 multinational randomized phase III clinical trials looking for cardiovascular adverse events in groups that received abiraterone, enzalutamide, apalutamide and darolutamide for treatment of prostate cancer. We analyzed a cohort of 9867 patients in these trials. Results: In the abiraterone usage group (n= 3492), most common cardiovascular adverse event was hypertension reported in 16.03%. Atrial fibrillation was reported in 0.97% and other cardiovascular events (IHD, MI, SVT, VT, and heart failure) were seen in 9.56%. In the enzalutamide usage group (n=4094) hypertension was seen in 10.6%, IHD in 1.88%, and atrial fibrillation was seen in 0.39%. Other unspecified cardiovascular adverse events were reported in 5.98%. In the apalutamide usage group (n=1327) hypertension was seen in 22%. Other cardiovascular adverse events (atrial fibrillation, MI, cardiogenic shock) were seen in 0.96%. In the darolutamide usage group (n=954) hypertension was seen in 6.6%, coronary artery disorders (coronary artery disease, coronary artery occlusion and stenosis) in 3.24%, and heart failure in 1.88%. Conclusions: The most common cardiovascular adverse event with use of anti-androgen medication seen in this large cohort analysis was hypertension with highest incidence seen in apalutamide group. Other cardiovascular side-effects noted were atrial fibrillation, SVT, VT, ischemic heart disease, MI, heart failure, and cardiogenic shock. Abiraterone and enzalutamide are the drugs that have been used in most trials. FDA adverse reaction reporting system (FAERS) shows hypertension as the most commonly reported cardiovascular adverse event with abiraterone and enzalutamide use. More prospective studies are needed to further access cardiovascular risk with use of anti-androgen therapy.

Evolution of androgen receptor targeted therapy for advanced prostate cancer

2014 ◽  
Vol 11 (6) ◽  
pp. 365-376 ◽  
Author(s):  
Yien Ning Sophia Wong ◽  
Roberta Ferraldeschi ◽  
Gerhardt Attard ◽  
Johann de Bono
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Advanced Prostate Cancer

scholarly journals Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON

2020 ◽  
Vol 30 (4) ◽  
pp. 620-622
Author(s):  
Benjamin Condon ◽  
Grace Liskaser ◽  
Isaac A. Thangasamy ◽  
Declan G. Murphy
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Hormone Sensitive

The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS5084-TPS5084
Author(s):  
Rahul Raj Aggarwal ◽  
Joshi J. Alumkal ◽  
Russell Zelig Szmulewitz ◽  
Celestia S. Higano ◽  
Alan Haruo Bryce ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Hormone Sensitive

Abstract B4: Elevated expression of c-FLIP in castrate-resistant prostate cancer antagonizes response to androgen receptor-targeted therapy

2012 ◽  
Vol 72 (4 Supplement) ◽  
pp. B4-B4
Author(s):  
Clare McCourt ◽  
Pamela Maxwell ◽  
Roberta Mazzucchelli ◽  
Manuel Salto-Tellez ◽  
Joe O'Sullivan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Elevated Expression ◽  
Castrate Resistant Prostate Cancer ◽  
Castrate Resistant
Sign in / Sign up

Export Citation Format

Share Document